BioSpace News Archive

According to a new survey, only three percent of Americans receive information from government agencies about COVID-19 resources, tools and information.

Long-time St. Jude Children’s Research Hospital® supporter Sky High for Kids makes its mark in Memphis as the first organization to add its name to the Advanced Research Center, the new state-of-the-art facility opening later this year on the St. Jude campus.

GRIP Molecular is pleased to announce the formation of a Board of Directors with Edward Ludwig accepting the role of Chairman of the Board

Battelle recently has developed a microneutralization assay, which uses live SARS-CoV-2 virus to analyze the neutralizing response against the virus in human serum samples

ISBRG’s SpotLight-19© technology leverages advancements in optics and artificial intelligence to define a state of COVID-19 infection.

WATS3D, a diagnostic platform used by physicians to detect Barrett’s esophagus, pre-cancer and cancerous cells in the esophagus, has received a positive medically necessary designation from Blue Cross Blue Shield of Kansas City.

CANbridge Pharmaceuticals, Inc., a biopharmaceutical company developing and commercializing innovative drugs to treat rare diseases and targeted cancers in China and globally, announced that the first subject has been dosed in the Phase I trial of CAN106 in Singapore, which is being developed for the treatment of complement dysregulation diseases.

Agilent Completes CE-IVD Registration of qRT-PCR In Vitro Diagnostic Kit for SARS-CoV-2 RNA Detection Kit expands Agilent’s product portfolio aimed at COVID-19 detection

No royalty payments due for 36 months Company has started to identify key opinion leader physicians in the US as well as Europe focused on addressing the symptoms - including gastrointestinal distress - that afflict a significant proportion of COVID-19 survivors for an extended period after recovery SAN FRANCISCO, CA / ACCESSWIRE / March 9, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”) today announced that the Company has signed the definitive

Exicure, Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced the appointments of Elizabeth (Betsy) Garofalo, M.D. and Mr. Andrew Sassine to its Board of Directors.